Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatment

Selection for time-limited & continuous therapy in CLLПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Clinical trial updates and time-limited therapy in CLLПодробнее

Time-limited vs continuous therapy in CLL treatmentПодробнее

Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimensПодробнее

Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial?Подробнее

Ongoing trials investigating the efficacy of pirtobrutinib in CLLПодробнее

Moving towards time-limited treatment in frontline CLLПодробнее

Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trialПодробнее

An insight into time-limited therapy in CLLПодробнее

Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN StudyПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLLПодробнее

BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLLПодробнее

Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trialПодробнее

The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLLПодробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее

Unanswered questions in frontline CLL treatmentПодробнее

Pirtobrutinib resistance in CLL: early findingsПодробнее